Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

References

• Fleischer, D, Umar, S. Esophageal cancer: epidemiology, pathogenesis and prevention. Nature Clin Pract Gastroenterol Hepatol 2008:5;517–525.
   PubMedGoogle Scholar
• International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed March 2 2015.
   Google Scholar
• Surveillance, Epidemiology, and End Results Program. National Cancer Institute. SEER Stat Fact Sheets: Esophageal Cancer 2014. Available at http://seer.cancer.gov/statfacts/html/esoph.html. Accessed March 2, 2015.
   Google Scholar
• Rustgi, AK, El-Serag, HB. Esophageal carcinoma. N Engl J Med 2014;371:2499–2509.
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992:326:1593–1598.
   PubMed Web of Science ®Google Scholar
• Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.
   PubMed Web of Science ®Google Scholar
• Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007:18;93–98.
   PubMed Web of Science ®Google Scholar
• Michel P, Adenis A, Di Flore F, Boucher E, Galais MP, Dahan L, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. British J Cancer 2006;95:705–709.
   PubMed Web of Science ®Google Scholar
• Ilson D, Minsky B, Kelsen D. Irinotecan, cisplatin, and radiation in esophageal cancer. Oncol 2002:16;11–15.
   Google Scholar
• Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, et al. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer. Cancer Invest 2010:28;820–827.
   PubMed Web of Science ®Google Scholar
• Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 2004;5:51–55.
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Barton JH, Patton JF, Zubkus JD, Simons L, et al. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2010;5:841–845.
   PubMed Web of Science ®Google Scholar
• Martin A, Bellmunt J, Maroto J, Gallardo E, Brea M, Perez-Gracia J, et al. Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: safety and efficacy results from phase II. J Clin Oncol 2013 ASCO Ann Meeting Abstracts 2013;31:S4550.
   Google Scholar
• Louvet C, Andre T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, et al. Phase II study of biweekly pemetrexed plus irinotecan as second-line therapy for metastatic colorectal cancer. J Oncol 2010;785934;1–7.
   Google Scholar
• Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007;13:515–522.
   PubMed Web of Science ®Google Scholar
• Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomized phase 2/3 trial. Lancet Oncol 2014;15:305–314.
   PubMed Web of Science ®Google Scholar
• Khushalani N, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844–2850.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 2000;6(7):2677–2684.
   PubMed Web of Science ®Google Scholar
• Avendano C, Menendez JC. Medicinal Chemistry of Anticancer Drugs, Amsterdam: Elsevier, 2008; p. 37.
   Google Scholar
• Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110(1);65–70.
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol 2014;32(25):2744–2749.
   PubMed Web of Science ®Google Scholar
• Babiker HM, Kovoor AI, Green MR, Dragovich T, Brown TD, Elquza E, et al. Phase I study of concomitant pemetrexed and cisplatin plus radiation in patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinomas. J Clin Oncol (Meeting Abstracts) 2014;32, 3_suppl 145.
   PubMed Web of Science ®Google Scholar